Alterity Therapeutics Limited American Depositary Shares (ATHE) is a publicly traded Healthcare sector company. As of July 7, 2026, ATHE trades at $5.70 with a market cap of $97.15M and a P/E ratio of 0.00. ATHE moved +0.00% today. Year to date, ATHE is +92.48%; over the trailing twelve months it is +46.89%. Its 52-week range spans $1.00 to $7.00. Analyst consensus is strong buy with an average price target of $12.67. Rallies surfaces ATHE's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
FDA Confirms Single Pivotal Phase 3 Trial for Alterity’s ATH434, Year-End 2026 Start: Official FDA minutes confirm Alterity’s Phase 3 protocol for ATH434 in MSA, endorsing a single pivotal trial supported by confirmatory evidence to underpin an NDA filing. The 200-patient, 12-month study (50 mg BID) with UMSARS Part II primary endpoint is on track to start by year-end 2026.
| Metric | Value |
|---|---|
| Price | $5.70 |
| Market Cap | $97.15M |
| P/E Ratio | 0.00 |
| EPS | $0.00 |
| Dividend Yield | 0.00% |
| 52-Week High | $7.00 |
| 52-Week Low | $1.00 |
| Volume | 4.84K |
| Avg Volume | 0 |
| Revenue (TTM) | $0 |
| Net Income | $0 |
| Gross Margin | 0.00% |
3 analysts cover ATHE: 0 strong buy, 3 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $12.67.